A Drug Utilization Study to Evaluate Indicators of Adherence to the Risk Minimization Measures for Ritlecitinib Using Electronic Healthcare Data in Denmark, France, and Sweden

21/05/2025
21/10/2026
EU PAS number:
EUPAS1000000523
Study
Planned
Subscribe
Download as PDF
Study identification

EU PAS number

EUPAS1000000523

Study ID

1000000523

Official title and acronym

A Drug Utilization Study to Evaluate Indicators of Adherence to the Risk Minimization Measures for Ritlecitinib Using Electronic Healthcare Data in Denmark, France, and Sweden

DARWIN EU® study

No

Study countries

Denmark
France
Sweden

Study description

This is a descriptive drug utilization study using secondary data from healthcare databases in Denmark, France, and Sweden.
This study will utilize routinely collected electronic healthcare data from national or regional population-based electronic healthcare registers.
The study aims to evaluate indicators of adherence to the routine and additional routine risk minimization measures for ritlecitinib in three EU countries: Denmark, France, and Sweden.

Study status

Planned
Research institutions and networks

Institutions

Pfizer
First published:
01/02/2024
Institution

Contact details

Cherise Wong

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer 100%
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)